Zoetis Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
Zoetis Inc. (ZTS) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of 0.30% for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-13.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2024-02-13
- Zoetis Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was 0.30%, a 50.00% decline from fiscal 2022.
- Zoetis Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was 0.60%, a 33.33% decline from fiscal 2021.
- Zoetis Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2021 was 0.90%, a 30.77% decline from fiscal 2020.
- Zoetis Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2020 was 1.30%, a 30.00% increase from fiscal 2019.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2023-12-31 | 0.30% 10-K · filed 2024-02-13 | |
| 2022-12-31 | 0.60% 10-K · filed 2024-02-13 | |
| 2021-12-31 | 0.90% 10-K · filed 2024-02-13 | |
| 2020-12-31 | 1.30% 10-K · filed 2023-02-14 | |
| 2019-12-31 | 1.00% 10-K · filed 2022-02-15 | |
| 2018-12-31 | 0.80% 10-K · filed 2021-02-16 | -0.80% 10-K · filed 2019-02-14 |
| 2017-12-31 | 0.50% 10-K · filed 2020-02-13 | -0.50% 10-K · filed 2018-02-15 |
| 2016-12-31 | -0.50% 10-K · filed 2019-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |